Loading clinical trials...

Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil | Clinical Trials | Clareo Health

COMPLETED

Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil

Real-world Data of Moderate to Severe Inflammatory Bowel Disease in Brazil: a Non-interventional, Multicenter Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life (RISE BR)

NCT02822235•Takeda

View on ClinicalTrials.gov

Summary

The purpose of this study is to gather information regarding the population with moderate to severe inflammatory bowel disease (IBD), the burden of the disease, and understand their treatment patterns, particularly on the use of available biologic therapies.

Detailed Description

This is a non-interventional study to determine the rate of control of disease activity in moderate to severe inflammatory bowel disease (IBD) participants, with two parts: cross-sectional evaluation (Day 1) with retrospective data collection and a prospective 12-month evaluation for patients with active IBD at cross-sectional evaluation (Day 1). The study enrolled 407 patients. This multicenter trial was conducted in Brazil. Retrospective data of previous IBD treatments (drug, dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years will be collected. Prospective data was collected for a period of 12 months in participants with active disease. UC participants, with no or light disease activity at Day 1 did not continue to 12-month follow up. CD participants, with no or light disease activity at Day 1 but with colonoscopy or calprotectin levels (i.e, calprotectin \>200 ug/g) in the previous year suggestive of inadequate control of activity progressed to 12-month follow up.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male or female.
•2. 18 years or older (at the time of diagnosis of moderate to severe UC or CD).
•3. Diagnosis of moderate to severe CD or UC for at least 6 months prior to Day 1 appointment according the clinical or endoscopic \\ criteria.
•4. Has provided the written informed consent. For the prospective period, eligible participants should present at least one of the following criteria that will only be applied at Day 1:
•5. For CD participants:
•* Harvey Bradshaw Index (HBI) ≥8 or
•* Crohn's Disease Activity Index (CDAI) ≥220 or Considering that for CD participants, the disease activity may not be clearly documented only with clinical data, some objective criteria may be considered as entry criteria for the 12-month prospective period:
•* Colonoscopy in the previous year suggestive of inadequate control of activity or,
•* Calprotectin levels in the previous year suggestive of inadequate control of activity (i.e, calprotectin \>200 µg/g).
•6. For UC: partial Mayo Score ≥5.
+1 more criteria

Exclusion Criteria

•1. Indeterminate or not classified colitis.
•2. Current or previous participation in interventional clinical trial (within the last 3 years). In addition, for the 12-month prospective period, participants will be excluded if:
•3. Presenting mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•4. Hospitalized participants at Day 1.
•5. Current off label treatment with Vedolizumab.
•Study Discontinuation Criteria It will be considered a premature termination the situation in which the participant discontinues the participation, i.e. they are withdrawn from the study before completing the 12 months of follow up period (365 days ± 14 days from Day 1), due to any of the reasons listed below:
•1. Withdrawal of consent: participants who for any reason withdraw the free and informed consent;
•2. Lost to follow-up (no return of the participant on the expected date of visit - drop-out from the protocol);
•3. Death;
•4. Study termination;
+1 more criteria

Locations (13)

Salvador, Estado de Bahia, Brazil

Goiânia, Goiás, Brazil

Belo Horizonte, Minas Gerais, Brazil

Juiz de Fora, Minas Gerais, Brazil

Curitiba, Paraná, Brazil

Teresina, Piauí, Brazil

Porto Alegre, Rio Grande do Sul, Brazil

Botucatu, São Paulo, Brazil

Ribeirão Preto, São Paulo, Brazil

Santo André, São Paulo, Brazil

Key Dates

Start Date

October 11, 2016

Primary Completion Date

February 5, 2018

Completion Date

February 19, 2018

Last Updated

February 25, 2020

Enrollment

407

ACTUAL participants

Conditions

Inflammatory Bowel Disease

Interventions

No Intervention

OTHER

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITINGNA

Impact of Morning Light Therapy in IBD

NCT07207200

Inflammatory Bowel Disease

View study

RECRUITING

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Impact of Morning Light Therapy in IBD

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

A Phase I Study of HW201877 in Healthy Subjects